8-K: Compass Therapeutics: Tovecimig Shows Promise in Biliary Tract Cancer Study

Compass Therapeutics announced positive Phase 2/3 data for tovecimig in combination with paclitaxel for biliary tract cancer, meeting key PFS endpoint and showing significant ORR.

Summary

• Compass Therapeutics announced results from its Phase 2/3 randomized trial (COMPANION-002) for tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer (BTC) who received prior chemotherapy.
• The study met its primary endpoint of Overall Response Rate (ORR), showing 17.1% ORR for tovecimig plus paclitaxel versus 5.3% for paclitaxel alone (p=0.031).
• A key secondary endpoint, Progression-Free Survival (PFS), also showed a statistically significant improvement with a median of 4.7 months for the combination arm compared to 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), representing a 56% reduction in the risk of progression.
• Overall Survival (OS) secondary endpoint was confounded by a high crossover rate (54%) from the control arm to the tovecimig arm, with 85% of all patients ultimately receiving tovecimig.
• In a subset analysis of patients who crossed over from the control arm, those who received tovecimig showed a statistically significant improvement in median OS of 12.8 months compared to 6.1 months for those who did not crossover.
• Tovecimig was generally well-tolerated, with a safety profile consistent with prior studies. Common adverse events included hypertension and fatigue.
• Compass plans to meet with the FDA to discuss these data ahead of a planned Biologics License Application (BLA) submission.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with strong efficacy signals in ORR and PFS, and promising subset OS data, despite the OS endpoint being confounded by crossover.

Positives

• The combination of tovecimig and paclitaxel demonstrated a statistically significant improvement in Overall Response Rate (ORR) of 17.1% compared to 5.3% for paclitaxel alone (p=0.031).
• Progression-Free Survival (PFS) was significantly improved, with a median of 4.7 months for the tovecimig combination versus 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), a 56% reduction in progression risk.
• In a subset analysis, patients who crossed over to tovecimig from the control arm showed a significantly improved median Overall Survival (OS) of 12.8 months compared to 6.1 months for non-crossover patients.
• The safety profile of tovecimig was consistent with prior studies and generally well-tolerated, with no new safety signals identified.
• The pooled median OS for all patients in the study who received tovecimig (85% of participants) was 8.9 months, which is noted as substantially longer than chemotherapy benchmarks of approximately 6 months.

Negatives

• The Overall Survival (OS) secondary endpoint did not meet statistical significance due to a high crossover rate (54%) from the control arm to the tovecimig arm.
• The ITT OS analysis showed a median OS of 8.9 months for the tovecimig combination arm versus 9.4 months for the control arm (HR=1.05, p=0.78).
• The RPSFT OS analysis, intended to adjust for crossover, also showed a median OS of 8.9 months versus 9.4 months for paclitaxel alone (HR=1.13, p=0.65), with its validity questioned due to unmet assumptions.

Risks

• The company's ability to raise additional funding needed to continue its business and product development plans.
• The inherent uncertainties associated with developing product candidates and operating as a development stage company.
• Competition in the industry in which Compass operates and general market conditions.
• The validity of the RPSFT OS analysis was questioned due to unmet assumptions, potentially impacting the interpretation of crossover-adjusted results.

Future Outlook

Compass Therapeutics intends to meet with the U.S. Food and Drug Administration (FDA) to discuss the COMPANION-002 study data in advance of a planned Biologics License Application (BLA) submission. The company also expects to present the complete dataset at a medical conference later this year.

Management Comments

• "In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC."
• "The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in their tumor."
• "It is also notable that the 31 crossover patients survived a median of 12.8 months, similar to the median OS seen in front-line studies in this setting."
• "These findings reinforce our belief that tovecimig can address a significant unmet need for patients with limited and insufficient treatment options."
• "We are now focused on engaging with the FDA to bring this much needed therapy to the cholangiocarcinoma community as quickly as possible."
• "Patients with advanced biliary tract cancer have an urgent need for better treatment options. These results are a significant step forward and I anticipate that, if approved, it will meaningfully change the way physicians care for these patients."
• "I also applaud Compass for putting patients first in the design of this study by allowing patients to crossover to receive treatment with tovecimig. These patients clearly benefited from this innovative therapy."

Industry Context

StockSavvy.ai notes that the results for tovecimig in biliary tract cancer are significant given the limited treatment options in the second-line setting for patients without actionable mutations. The observed ORR and PFS improvements, particularly the strong subset OS data in crossover patients, suggest potential for tovecimig to address a critical unmet need in this oncology indication.

Comparison to Industry Standards

• In the second-line setting for biliary tract cancer without actionable mutations, historical data for chemotherapy benchmarks (like FOLFIRI or FOLFOX) show an Overall Response Rate (ORR) of approximately 5% or less and a median Overall Survival (OS) of around six months.
• Compass's tovecimig combination achieved an ORR of 17.1% and a pooled median OS of 8.9 months, exceeding these benchmarks.
• The median PFS of 4.7 months for the tovecimig combination is a substantial improvement over the 2.6 months seen with paclitaxel alone and is notably better than historical PFS data for other second-line therapies.
• The median OS of 12.8 months observed in crossover patients who received tovecimig is significantly higher than the 6.1 months for non-crossover patients and compares favorably to OS seen in some front-line studies.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results that could lead to regulatory approval and commercialization of a new therapy.
• Patients: Potential for a new, more effective treatment option for biliary tract cancer patients in the second-line setting.
• Healthcare Providers: May lead to a new standard of care for treating advanced biliary tract cancer.
• Regulators (FDA): Will review the data for potential approval of tovecimig.

Next Steps

• Meet with the U.S. Food and Drug Administration (FDA) to discuss the COMPANION-002 study data.
• Submit a Biologics License Application (BLA) to the FDA.
• Present the complete dataset from the COMPANION-002 study at a medical conference later this year.

Key Dates

Recommendation

The results are encouraging, particularly the PFS and ORR, and the subset OS data is compelling. However, the primary OS endpoint was not met due to crossover, and the company still faces the significant hurdle of FDA approval and the need for further funding. A 'hold' allows investors to await FDA feedback and further strategic developments before making a stronger commitment.

Keywords

Compass Therapeutics, Tovecimig, Biliary Tract Cancer, Phase 2/3 Study, Oncology, Biopharmaceutical, Progression-Free Survival, Overall Response Rate